XTLB revenueFY2025$60.0K
- FY YoY
- -86.7%
XTLB revenue was $60.0K for fiscal 2025 (ended Dec 31, 2025), down 86.7% from fiscal 2024. It rose in 2 of the last 3 fiscal years.
XTL Biopharmaceuticals Ltd. (XTLB) financials
For fiscal 2025 (ended Dec 31, 2025), XTL Biopharmaceuticals Ltd. reported $60.0K of revenue and -$6.97M of net income.
- Revenue, FY2025
- $60.0K
- Revenue growth, YoY
- -86.7%
- Net income, FY2025
- -$6.97M
- Net margin
- -11615.0%
- EPS, diluted, FY2025
- -$0.01
- Cash
- $76.0K
- P/S
- 62.67
- Market cap
- $3.8M
FY2022FY2025
FY2016FY2025
FY2016FY2024
XTLB revenue and earnings growth
XTLB net incomeFY2025-$6.97M
XTLB net income was -$6.97M for fiscal 2025 (ended Dec 31, 2025), compared with -$1.03M in fiscal 2024.
XTLB EPSFY2025-$0.01
XTLB diluted EPS was -$0.01 for fiscal 2025 (ended Dec 31, 2025), compared with -$0.00 in fiscal 2024.
XTLB free cash flowFY2024-$1.67M
XTLB free cash flow was -$1.67M for fiscal 2024 (ended Dec 31, 2024).
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $60.0K | $451.0K | $41.0K | $36.0K | - | - | - | - | - | - |
| Cost of revenue | - | $448.0K | - | - | - | - | - | - | - | - |
| Gross profit | - | $3.0K | - | - | - | - | - | - | - | - |
| Research and development | $28.0K | $16.0K | $31.0K | $30.0K | $30.0K | $38.0K | $35.0K | $38.0K | $43.0K | $443.0K |
| Selling, general and admin | $1.44M | $759.0K | $734.0K | $850.0K | $1.00M | $910.0K | $807.0K | $755.0K | $1.20M | $1.27M |
| Operating income | -$1.69M | -$775.0K | -$765.0K | -$880.0K | -$1.03M | -$948.0K | -$842.0K | -$793.0K | -$1.25M | -$2.56M |
| Interest expense | $7.0K | $112.0K | $1.06M | $1.56M | $21.0K | $2.19M | $603.0K | $35.0K | $337.0K | $7.0K |
| Pre-tax income | -$759.0K | $240.0K | -$1.78M | -$1.35M | - | - | - | - | - | - |
| Income tax | - | -$130.0K | - | - | - | - | - | - | - | - |
| Net income | -$6.97M | -$1.03M | -$1.78M | -$1.35M | $435.0K | -$2.95M | -$763.0K | $3.63M | -$781.0K | -$2.54M |
| EPS, basic | -$0.01 | -$0.00 | -$0.00 | -$0.00 | $0.00 | -$0.01 | -$0.00 | - | - | - |
| EPS, diluted | -$0.01 | -$0.00 | -$0.00 | -$0.00 | $0.00 | -$0.01 | -$0.00 | - | - | - |
| Diluted shares | 896.2M | 673.0M | 544.9M | 544.9M | 615.5M | 514.2M | 514.2M | 514.2M | 470.2M | 274.0M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $76.0K | $371.0K | $1.40M | $2.09M | $2.97M | $3.63M | $4.46M | $3.25M | $3.29M | $2.02M |
| Short-term investments | - | - | - | - | - | $2.41M | $2.27M | - | - | - |
| Current assets | $166.0K | $1.34M | $2.05M | $3.81M | $6.24M | $6.12M | $6.83M | $8.20M | $6.21M | $2.75M |
| Goodwill | - | $3.19M | - | - | - | - | - | - | - | - |
| Total assets | $166.0K | $8.55M | $2.43M | $4.19M | $6.62M | $6.50M | $7.21M | $8.57M | $6.59M | $3.02M |
| Current liabilities | - | $2.21M | $206.0K | - | - | - | - | - | $300.0K | $330.0K |
| Total debt | - | $138.0K | - | - | - | - | - | - | - | - |
| Total liabilities | $420.0K | $3.12M | $206.0K | $187.0K | $1.28M | $2.89M | $697.0K | $1.30M | $2.97M | $330.0K |
| Shareholders' equity | -$254.0K | $5.43M | $2.22M | $4.00M | $5.33M | $3.61M | $6.51M | $7.27M | $3.62M | $2.69M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.02M | -$1.62M | -$707.0K | -$901.0K | -$1.05M | -$850.0K | -$908.0K | -$816.0K | -$1.13M | -$1.73M |
| Capital expenditures | - | $54.0K | - | - | - | $1.0K | $2.0K | - | - | $2.0K |
| Free cash flow | - | -$1.67M | - | - | - | -$851.0K | -$910.0K | - | - | -$1.73M |
| Investing cash flow | $522.0K | -$844.0K | $41.0K | $36.0K | $8.0K | $32.0K | $2.11M | $778.0K | -$2.50M | -$66.0K |
| Financing cash flow | $208.0K | $1.45M | - | - | $385.0K | - | - | - | $4.89M | - |
| Stock-based compensation | $346.0K | $264.0K | $3.0K | $14.0K | $37.0K | $51.0K | $5.0K | $22.0K | $39.0K | $127.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -86.7% | 1000.0% | 13.9% | - | - | - | - | - | - | - |
| Gross margin | - | 0.7% | - | - | - | - | - | - | - | - |
| Operating margin | -2813.3% | -171.8% | -1865.9% | -2444.4% | - | - | - | - | - | - |
| Net margin | -11615.0% | -227.7% | -4346.3% | -3744.4% | - | - | - | - | - | - |
| Free cash flow margin | - | -370.7% | - | - | - | - | - | - | - | - |
| Return on equity | - | -18.9% | -80.3% | -33.7% | 8.2% | -81.8% | -11.7% | 49.9% | -21.6% | -94.7% |
| Return on assets | -4198.2% | -12.0% | -73.5% | -32.2% | 6.6% | -45.4% | -10.6% | 42.3% | -11.9% | -84.4% |
| Current ratio | - | 0.61 | 9.93 | - | - | - | - | - | 20.69 | 8.35 |
| Debt to equity | - | 0.03 | - | - | - | - | - | - | - | - |
Source: XBRL data XTL Biopharmaceuticals Ltd. files with the SEC, latest filing dated Jun 30, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
XTLB peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| XTLB | $60.0K | -86.7% | -$6.97M | -11615.0% | $3.8M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
XTLB FAQ
7 questionsWhat is XTLB revenue?
XTL Biopharmaceuticals Ltd. (XTLB) reported $60.0K of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 86.7% from the year before.Is XTLB profitable?
No. XTL Biopharmaceuticals Ltd. reported a net loss of $6.97M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does XTLB have?
XTL Biopharmaceuticals Ltd. reported $76.0K in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is XTLB revenue growing?
XTL Biopharmaceuticals Ltd.'s revenue changed -86.7% in fiscal 2025, to $60.0K.What is XTLB earnings per share?
Diluted earnings per share were -$0.01 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did XTLB last report financial results?
The latest statements here come from XTL Biopharmaceuticals Ltd.'s 20-F filed on Jun 30, 2026, covering the period ended Dec 31, 2025.Where does this XTLB financial data come from?
Quantisnow builds these statements from the structured XBRL data XTL Biopharmaceuticals Ltd. files with the SEC. It is provided for information only and is not investment advice.